ProfileGDS4814 / ILMN_1722200
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 3% 11% 30% 31% 30% 3% 8% 38% 5% 15% 5% 5% 1% 10% 9% 19% 10% 6% 6% 13% 9% 30% 3% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)38.57363
GSM780708Untreated after 4 days (C2_1)41.326411
GSM780709Untreated after 4 days (C3_1)45.649430
GSM780719Untreated after 4 days (C1_2)45.803331
GSM780720Untreated after 4 days (C2_2)45.562530
GSM780721Untreated after 4 days (C3_2)38.48563
GSM780710Trastuzumab treated after 4 days (T1_1)40.55968
GSM780711Trastuzumab treated after 4 days (T2_1)47.24238
GSM780712Trastuzumab treated after 4 days (T3_1)39.25925
GSM780722Trastuzumab treated after 4 days (T1_2)42.411115
GSM780723Trastuzumab treated after 4 days (T2_2)39.39985
GSM780724Trastuzumab treated after 4 days (T3_2)39.60665
GSM780713Pertuzumab treated after 4 days (P1_1)33.82441
GSM780714Pertuzumab treated after 4 days (P2_1)41.149610
GSM780715Pertuzumab treated after 4 days (P3_1)40.87979
GSM780725Pertuzumab treated after 4 days (P1_2)43.44119
GSM780726Pertuzumab treated after 4 days (P2_2)41.108710
GSM780727Pertuzumab treated after 4 days (P3_2)39.94356
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.00826
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)42.000813
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)40.82129
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)45.586130
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)38.25773